ArticleWorld journal of gastrointestinal oncology2013
Risk factors and classifications of hilar cholangiocarcinoma.
Article in World journal of gastrointestinal oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Efficacy and safety of irreversible electroporation in unresectable perihilar cholangiocarcinoma: a systematic review and meta-analysis.The British journal of radiology · 2024Pooled it
- Cholecystitis and cholangiocarcinoma: a two-sample Mendelian randomization study.BMC gastroenterology · 2025Article
- Prognostic factors in patients with intrahepatic cholangiocarcinoma.Scientific reports · 2024Article
- Role of Intraoperative Frozen Section Assessment of Proximal Bile Duct Margins and the Impact of Additional Re-Resection in Perihilar Cholangiocarcinomas.Indian journal of surgical oncology · 2024Article
- Radiographic features predictive of recurrence and survival after surgical resection of perihilar cholangiocarcinoma.Heliyon · 2024Article
- ASO Author Reflections: Total Laparoscopic Resection of Perihilar Cholangiocarcinoma: What is Ahead?Annals of surgical oncology · 2023Article
- New Imaging Techniques.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2023Article
- Non-surgical treatment of hilar cholangiocarcinoma.World journal of gastrointestinal oncology · 2021Review
- Liver Transplantation for Peri-hilar Cholangiocarcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Review
- The association between circulating MicroRNA-150 level and cholangiocarcinoma.Journal of clinical laboratory analysis · 2020Article
- Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma.World journal of gastroenterology · 2020Article
- 16S rDNA microbiome composition pattern analysis as a diagnostic biomarker for biliary tract cancer.World journal of surgical oncology · 2020Article
- Clinical efficacy of gemcitabine and cisplatin-based transcatheter arterial chemoembolization combined with radiotherapy in hilar cholangiocarcinoma.World journal of gastrointestinal oncology · 2019Article
- Observational
- Extrahepatic cancers and chronic HCV infection.Nature reviews. Gastroenterology & hepatology · 2018Review
- Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease.Annals of surgery · 2018Article
- Preoperative prediction of curative surgery of perihilar cholangiocarcinoma by combination of endoscopic ultrasound and computed tomography.United European gastroenterology journal · 2018Article
- Serum albumin predicts survival in patients with hilar cholangiocarcinoma.Gastroenterology report · 2017Article
- Robotic radical resection for hilar cholangiocarcinoma: perioperative and long-term outcomes of an initial series.Surgical endoscopy · 2016Article
- Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme.Journal of the American College of Surgeons · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma is the second most common primary malignant tumor of the liver. Perihilar cholangiocarcinoma or Klatskin tumor represents more than 50% of all biliary tract cholangiocarcinomas. A wide range of risk factors have been identified among patients with Perihilar cholangiocarcinoma including advanced age, male gender, primary sclerosing cholangitis, choledochal cysts, cholelithiasis, cholecystitis, parasitic infection (Opisthorchis viverrini and Clonorchis sinensis), inflammatory bowel disease, alcoholic cirrhosis, nonalcoholic cirrhosis, chronic pancreatitis and metabolic syndrome. Various classifications have been used to describe the pathologic and radiologic appearance of cholangiocarcinoma. The three systems most commonly used to evaluate Perihilar cholangiocarcinoma are the Bismuth-Corlette (BC) system, the Memorial Sloan-Kettering Cancer Center and the TNM classification. The BC classification provides preoperative assessment of local spread. The Memorial Sloan-Kettering cancer center proposes a staging system according to three factors related to local tumor extent: the location and extent of bile duct involvement, the presence or absence of portal venous invasion, and the presence or absence of hepatic lobar atrophy. The TNM classification, besides the usual descriptors, tumor, node and metastases, provides additional information concerning the possibility for the residual tumor (R) and the histological grade (G). Recently, in 2011, a new consensus classification for the Perihilar cholangiocarcinoma had been published. The consensus was organised by the European Hepato-Pancreato-Biliary Association which identified the need for a new staging system for this type of tumors. The classification includes information concerning biliary or vascular (portal or arterial) involvement, lymph node status or metastases, but also other essential aspects related to the surgical risk, such as remnant hepatic volume or the possibility of underlying disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.